Trending...
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate - 134
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight - 127
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory - 121
ANN ARBOR, Mich.--(BUSINESS WIRE)--OcuSciences, Inc., a medical device company developing retinal imagers to detect early disease by assessing retinal metabolic activity, today announced the publication of a rare inherited mitochondrial diseases study in Ophthalmology Genetics journal. These findings suggest that the novel FPF measure can differentiate between patients diagnosed with inherited retinal dystrophies and their age-matched controls. Furthermore, the FPF results correlated with fundus autofluorescence findings, suggesting clinical utility of the rapid, automated measure.
This observational study, led by Elias Traboulsi, M.D., M.Ed., Director of the Center for Genetic Eye Diseases at Cleveland Clinic Cole Eye Institute, included 157 patients with genetically confirmed rod-cone dystrophy, Stargardt disease, Bardet-Biedl syndrome (BBS), and Mitochondrial ATP synthase mutation. Patients were imaged with the OcuMet Beacon, OcuSciences' flagship functional retinal imager, between January and December 2021 to capture and quantify their FPF signal. Mean FPF intensity and heterogeneity was significantly higher in patients with inherited retinal dystrophies than age-matched controls.
More on Michimich.com
"These findings suggest that flavoprotein fluorescence could be used as an additional tool in the assessment and diagnosis of patients with inherited retinal dystrophies," said Dr. Traboulsi. "More studies are needed that will help elucidate how this imaging modality could be implemented clinically and if there are opportunities to use FPF as a monitoring tool in these types of diseases."
The OcuMet Beacon is an automated, rapid retinal imager that assesses mitochondrial function by interrogating flavoproteins. The device emits a very specific wavelength of light that selectively excites flavoproteins in retinal mitochondria that are dysfunctional and hence cannot efficiently produce ATP. The flavoproteins in dysfunctional mitochondria emit a specific wavelength that the device then captures and quantifies. Mitochondrial dysfunctional has been documented as a precursor to apoptosis, or cell death.
The OcuMet Beacon is currently being used under Institutional Review Board at Cole Eye Institute.
About OcuSciences, Inc.
OcuSciences, Inc., is a commercial-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the early detection of disease. Its flagship device, the OcuMet Beacon, has being developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluorescence (FPF), a well-studied precursor to retinal cell death, in a patient's eye. OcuSciences has shown preliminary clinical utility in a number of different disease states, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Learn more at www.ocusciences.com.
More on Michimich.com
Contacts
Kurt Riegger
(734) 623-9434
info@ocusciences.com
This observational study, led by Elias Traboulsi, M.D., M.Ed., Director of the Center for Genetic Eye Diseases at Cleveland Clinic Cole Eye Institute, included 157 patients with genetically confirmed rod-cone dystrophy, Stargardt disease, Bardet-Biedl syndrome (BBS), and Mitochondrial ATP synthase mutation. Patients were imaged with the OcuMet Beacon, OcuSciences' flagship functional retinal imager, between January and December 2021 to capture and quantify their FPF signal. Mean FPF intensity and heterogeneity was significantly higher in patients with inherited retinal dystrophies than age-matched controls.
More on Michimich.com
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
"These findings suggest that flavoprotein fluorescence could be used as an additional tool in the assessment and diagnosis of patients with inherited retinal dystrophies," said Dr. Traboulsi. "More studies are needed that will help elucidate how this imaging modality could be implemented clinically and if there are opportunities to use FPF as a monitoring tool in these types of diseases."
The OcuMet Beacon is an automated, rapid retinal imager that assesses mitochondrial function by interrogating flavoproteins. The device emits a very specific wavelength of light that selectively excites flavoproteins in retinal mitochondria that are dysfunctional and hence cannot efficiently produce ATP. The flavoproteins in dysfunctional mitochondria emit a specific wavelength that the device then captures and quantifies. Mitochondrial dysfunctional has been documented as a precursor to apoptosis, or cell death.
The OcuMet Beacon is currently being used under Institutional Review Board at Cole Eye Institute.
About OcuSciences, Inc.
OcuSciences, Inc., is a commercial-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the early detection of disease. Its flagship device, the OcuMet Beacon, has being developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluorescence (FPF), a well-studied precursor to retinal cell death, in a patient's eye. OcuSciences has shown preliminary clinical utility in a number of different disease states, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Learn more at www.ocusciences.com.
More on Michimich.com
- ACTIQO Launches on iOS to Help Families Manage Everything Around Kids' Activities
- Hillside Terrace Senior Living Offers Free Assisted Living Guide for Families Exploring Senior Care
- How a Lost Driver's License in Michigan After an OWI Can Impact Your Career
- ArborMotion Offers Complimentary Back-to-School Vehicle Inspections
- DC Norris North America to Help Manufacturers Supercharge Kettles at PACK EXPO International 2026
Contacts
Kurt Riegger
(734) 623-9434
info@ocusciences.com
Filed Under: Business
0 Comments
Latest on Michimich.com
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- The Great Junk Hunt Announces First-Ever Novi, Michigan Event for February 2027
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- What Did Detroit Teach KayeDinero About Being Human?
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- CIMdata to Host Educational Webinar on Navigating the Simulation Software Mega-Mergers One Year On
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- Squiggle Room Continues to Champion Play-Based Early Learning for Ann Arbor Families
- The JMAC Foundation Expands Martial Arts Scholarship Support for Students
- Network Services Group Highlights the Benefits of IT Outsourcing for Ann Arbor Small Businesses
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year